Yahoo Finance Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital
Leading provider of dialysis products and services, Fresenius Medical Care AG & Co. KGAA FMS, announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China. This is Fresenius Medical Care's first joint venture hospital in China.
Stock Performance
In the last three months, the price performance of Fresenius Medical was encouraging. The stock added 5.01% versus the Zacks classified Medical Instruments sub-industry’s gain of 4.71%.
However, the estimates revision trend for the stock lacks luster. The current quarter saw one estimate moving south over the last month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the current quarter dropped to 44 cents per share from 45 cents over the same time period.
More About the China Venture
Wuhua Hospital is a private Grade II hospital located in Wuhua district in the center of Kunming city. It is the capital of Yunnan province in south-west China.
The facility provides treatments to more than 8,000 chronic-disease patients and 70 dialysis patients. The scope of services includes internal medicine, nephrology, surgery, gynecology, dermatology, traditional Chinese medicine, physiotherapy, stomatology and others.
Fresenius Medical Care is a leading healthcare company, focusing on providing care to people with renal and other chronic conditions. The company has an extensive network of dialysis facilities, outpatient cardiac and vascular labs, urgent care centers, and the country’s largest collection of hospitalist and post-acute providers.
One of the world’s largest fully vertically integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals.
Key Picks
Currently, Fresenius Medical carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Inogen Inc. INGN, IDEXX Laboratories, Inc. IDXX and Fluidigm Corporation FLDM. Notably, Inogen and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.
IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an impressive 97.5% in the last one year.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Fluidigm Corporation (FLDM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
